Researchers hunt for new drugs for Leishmaniasis
According to an international survey by the BBVA Foundation conducted this year, citizens in advanced societies view assisted reproduction techniques in general and in vitro fertilization in particular as firmly acceptable alternatives for people with fertility problems (over 7 points on an acceptance scale from 0 to 10 in twelve of the fifteen survey countries).
Full Post: Attitudes towards assisted reproduction and preimplantation genetic diagnosis
Hundreds of millions of people, mainly in developing countries, are disabled by infectious diseases, according to the World Health Organization.
More than 12 million people in 88 countries are infected with leishmaniasis, a parasitic disease spread by the bite of infected sand flies. Nearly 2 million new cases are reported and about 70,000 people die from the disease annually.
Researchers at the University of Illinois at Chicago have discovered that compounds derived from a natural product can be used in developing a new drug to treat the disease.
Despite a worsening global impact of this disease, little progress has been made toward the development of new chemotherapeutics against it, says Alan Kozikowski, professor and director of UIC’s Drug Discovery Program and coordinator of the project.
Drugs compounded from the toxic metal antimony have been the first-line therapeutic option for more than 50 years.
“But antimonials may cause acute pancreatitis and cardiac arrhythmia and can sometimes lead to death,” Kozikowski said. Only recently, he said, have novel agents been added to the therapeutic arsenal.
Leishmaniasis can be cutaneus, which causes skin sores that leave ugly scars, or visceral, which is 100 percent fatal if left untreated.
Visceral leishmaniasis has increased in recent years due to emerging co-infections with HIV, spreading the disease to the developed countries in North America and southern Europe, Kozikowski said. The disease is normally found in tropical regions, from the rain forests in Central and South America to deserts in West Asia.
To find a starting point from which to develop a better drug, UIC postdoctoral researchers Suresh Tipparaju and Marco Pieroni synthesized a chemical “library” of more than 100 diverse compounds and screened them for biological activity against the Leishmania parasite. They observed high antiparasitic activity in a compound first isolated from streptomyces bacteria more than 20 years ago. That compound, Tipparaju said, could potentially be modified to treat leishmaniasis. It was already three times more active than miltefosine, a drug in current use, he said.
Miltefosine is the first oral drug to cure both visceral and cutaneus leishmaniasis. Despite the drug’s efficacy, Tipparaju said, miltefosine is limited by its persistence in the bloodstream and long-term side effects. It is also not effective when given to patients co-infected with HIV.
The UIC researchers are attempting to develop an antiparasitic agent that is less toxic than miltefosine and that can kill the parasite inside blood cells. In addition, the researchers are investigating the mechanism of action of the new candidate compounds through a collaboration with Manlio Tolomeo of the Center for Parasitic Diseases in Palermo, Italy. Mechanistic studies could lead to further improvement of promising agents, Tipparaju said.
Researchers from the University of Granada and the University of Barcelona have shown that treatment with maslinic acid, a triterpenoid compound isolated from olive-skin pomace, results in a significant inhibition of cell proliferation and causes apoptotic death in colon-cancer cells. Maslinic acid is a novel natural compound and it is able to induce apoptosis
Full Post: Compound from olive-skin pomace protects against colon-cancer
This year, the U.S. Food and Drug Administration is expected to approve the first malaria drug to contain artemisinin, a wormwood derivative from China that has proven effective for malaria in Africa and Asia. Although there are only about 1,500 reported cases of malaria treated in this country each year, this approval would also make
Full Post: First artemisinin based malaria drug may meet resistance, expert says
Older adults with symptoms of depression appear more likely to gain abdominal fat, but not overall fat, over a five-year period, according to a report in the December issue of Archives of General Psychiatry. About 10 percent to 15 percent of older adults have symptoms of depression, according to background information in the article. “Depression
Full Post: Seniors with depression more likely to gain abdominal fat
Researchers have reported positive results from a safety and efficacy study pertaining to tribendimidine, a broad-based treatment for intestinal worm infections. The group’s results demonstrate the success of the new drug from China versus that of the standard albendazole for the treatment of hookworm, large roundworm, whipworm, and, for the first time, threadworm and
Full Post: Tribendimidine shows promise for intestinal worm infections
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors. Associate Professor James Turkson’s compounds disrupt the formation and spread of breast cancer tumors in tests on mice. The compounds, S3I-201 and S3I-M2001, break up a cancer-causing protein called STAT3, and researchers have observed no
Full Post: New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.